Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb

References

• van Kuijk A A, Geurts A C, Bevaart B J, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: A systematic review of the literature. J Rehabil Med 2002; 34(2)51–61
   PubMed Web of Science ®Google Scholar
• Bhakta B B, Cozens J A, Chamberlain M A, Bamford J M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial.(erratum appears in J Neurol Neurosurg Psychiatry 2001 Jun;70(6):821). J Neurol, Neurosurg Psychiatry 2000; 69(2)217–221
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon M F, Elovic E, Kassicieh V D, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke (comment). N Eng J Med 2002; 347(6)395–400
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Ward A. Botulinum toxin in the management of spasticity in adults. Clin Med 2002; 2(2)128–130
   PubMed Web of Science ®Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Move Disord 1994; 9(2)213–217
   PubMed Web of Science ®Google Scholar
• Ashford S, Turner-Stokes L. Evaluation of goal attainment in management of spasticity with botulinum toxin: Use of Goal Attainment Scaling to demonstrate functional gains. Physiother Res Int 2006; 11: 14–23
   PubMedGoogle Scholar
• The management of adults with spasticity using botulinum toxin: A guide to clinical practice. (Full guidance supplement to Concise Guidelines for the use of botulinum toxin in the management of spasticity in adults, Royal College of Physicians, London). Radius Healthcare, SurreyUK 2001
   Google Scholar
• Macfarlane A, Turner-Stokes L, De Souza L. The associated reaction rating scale: A clinical tool to measure associated reactions in the hemiplegic upper limb. Clin Rehabil 2002; 16(7)726–735
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Jackson D. Assessment of shoulder pain in hemiplegia: Sensitivity of the ShoulderQ. Disabil Rehabil 2006; 28(6)389–395
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Rusconi S. Screening for ability to complete a questionnaire: A preliminary evaluation of the AbilityQ and ShoulderQ for assessing shoulder pain in stroke patients. Clin Rehabil 2003; 17(2)150–157
   PubMed Web of Science ®Google Scholar
• Jackson D, Horn S, Kersten P, Turner-Stokes L. Development of a pictorial scale of pain intensity [SPIN] to facilitate self-report in patients with impairments of language and cognition following stroke. Part I: Validation in a general population. Clin Med 2006; 6: 580–585
   PubMed Web of Science ®Google Scholar
• Kiresuk T, Smith A, Cardillo J. Goal attainment scaling: Application, theory and measurement. Lawrence Erlbaum Associates, New York 1994
   Google Scholar
• Jackson D, Turner-Stokes L, Williams H, Das-Gupta R. Use of an integrated care pathway: A third round audit of the management of shoulder pain in neurological conditions. J Rehabil Med 2003; 35(6)265–270
   PubMed Web of Science ®Google Scholar
• Bakheit A M, Thilmann A F, Ward A B, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31(10)2402–2406
   PubMed Web of Science ®Google Scholar
• Hesse S, Reiter F, Konrad M, Jahnke M T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomised, double-blind placebo-controlled study. Clin Rehabil 1998; 12: 381–388
   PubMed Web of Science ®Google Scholar
• Stark S. Physiotherapy and botulinum toxin in spasticity management. Brit J Ther Rehabil 2001; 8(10)386–392
   Google Scholar
• Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Move Disord 1998; 13(1)150–154
   PubMed Web of Science ®Google Scholar
• Kiresuk T, Sherman R. Goal attainment scaling: A general method of evaluating comprehensive mental health programmes. Commun Ment Health J 1968; 4: 443–453
   PubMed Web of Science ®Google Scholar
• Stolee P, Rockwood K, Fox R A, Streiner D L. The use of goal attainment scaling in a geriatric care setting. J Am Geriat Soc 1992; 40(6)574–578
   PubMed Web of Science ®Google Scholar
• Stolee P, Zaza C, Pedlar A, Myers A M. Clinical experience with Goal Attainment Scaling in geriatric care. J Aging Health 1999; 11(1)96–124
   PubMed Web of Science ®Google Scholar
• Williams R C, Steig R L. Validity and therapeutic efficiency of individual goal attainment procedures in a chronic pain treatment centre. Clin J Pain 1987; 2: 219–228
   Google Scholar
• Rockwood K, Joyce B, Stolee P. Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients. J Clin Epidemiol 1997; 50(5)581–588
   PubMed Web of Science ®Google Scholar
• Rushton P W, Miller W C. Goal attainment scaling in the rehabilitation of patients with lower-extremity amputations: A pilot study. Arch Phys Med Rehabil 2002; 83(6)771–775
   PubMed Web of Science ®Google Scholar
• Rockwood K, Stolee P, Fox R A. Use of goal attainment scaling in measuring clinically important change in the frail elderly (comment). J Clin Epidemiol 1993; 46(10)1113–1118
   PubMed Web of Science ®Google Scholar
• Gordon J E, Powell C, Rockwood K. Goal attainment scaling as a measure of clinically important change in nursing-home patients. Age Ageing 1999; 28(3)275–281
   PubMed Web of Science ®Google Scholar
• Wade D T. Evidence relating to goal-planning in rehabilitation. Clin Rehabil 1998; 12: 273–275
   PubMed Web of Science ®Google Scholar